4//SEC Filing
Mauro David J 4
Accession 0001209191-21-055307
CIK 0001678660other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 4:53 PM ET
Size
13.5 KB
Accession
0001209191-21-055307
Insider Transaction Report
Form 4
Mauro David J
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-09-07$36.92/sh−2,873$106,081→ 4,640 total - Sale
Common Stock
2021-09-07$37.79/sh−4,640$175,334→ 0 total - Exercise/Conversion
Common Stock
2021-09-07$1.89/sh+15,000$28,350→ 15,000 total - Sale
Common Stock
2021-09-07$35.91/sh−7,487$268,867→ 7,513 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-09-07−15,000→ 167,610 totalExercise: $1.89Exp: 2029-07-17→ Common Stock (15,000 underlying)
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $37.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Documents
Issuer
Prelude Therapeutics Inc
CIK 0001678660
Entity typeother
Related Parties
1- filerCIK 0001621172
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 4:53 PM ET
- Size
- 13.5 KB